Idec Zevalin May Need Central Monitoring Of Bio-Images, FDA Cmte. Suggests
Executive Summary
Idec should establish a centralized monitoring program to assess Zevalin biodistribution images, FDA Oncologic Drugs Advisory Committee Chair Stacy Nerenstone, MD, Helen & Harry Gray Cancer Center, suggested during the Sept. 11 review of the radioimmunotherapy.
You may also be interested in...
Idec Zevalin Approval Delayed By Manufacturing Issues At Catalytica
The delay in FDA approval of Idec's non-Hodgkin's lymphoma treatment Zevalin could also cause a delay in finalizing Medicare reimbursement for the product
Idec Zevalin Approval Delayed By Manufacturing Issues At Catalytica
The delay in FDA approval of Idec's non-Hodgkin's lymphoma treatment Zevalin could also cause a delay in finalizing Medicare reimbursement for the product
Idec, GSK, Corixa Discussing Licensing Of Radioimmunotherapy Patents
Idec is considering licensing patents from Corixa that may cover its radioimmunotherapy Zevalin.